PD 404182
Based on 1 publication(s) in Google Scholar
PD 404182 is a potent and competitive inhibitor of human dimethylarginine dimethylaminohydrolase 1 (DDAH1), with an IC50 of 9 μM. PD 404182 exhibits antiangiogenic and antiviral activity in vitro.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 98.26%
- CAS No.: 72596-74-8
- 화학식: C11H11N3S
- 분자량:217.29
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) PD 404182
MoreAll Antibiotic Isoforms
More
Biological Activity
IC50: 9 μM (DDAH1)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HeLa | CC50 |
>100 μM
Compound: 1, PD-404182
|
Cytotoxicity against human HeLa cells expressing CD4/CCR5
Cytotoxicity against human HeLa cells expressing CD4/CCR5
|
[PMID: 23022280] |
PD 404182 (20 μM) increases asymmetric dimethylarginine (ADMA) approximately 70% in ECs[1].
PD 404182 (50-100 μM; 18 hours) attenuates endothelial tube formation in virto and does not perturb cell membrane integrity or induces cytotoxicity[1].
PD 404182 inhibits HIV-1 in seminal plasma, with an IC50 of 1 μM[2].
PD 404182 (300 μM;30 minutes) exhibits low toxicity toward several human cell lines , freshly activated PBMCs, primary CD4+ T lymphocytes, macrophages, and dendritic cells, and lactobacilli found in the normal vaginal flora[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human dermal microvascular endothelial cells (ECs)
-
Concentration:10-300 μM
-
Incubation Time:24 hours
-
Result:Did not induce cytotoxicity.
Chemical Information
-
CAS No. 72596-74-8
-
Appearance Solid
-
분자량 217.29
-
화학식 C11H11N3S
-
Color Light yellow to yellow
-
SMILES
N=C1SC2=CC=CC=C2C3=NCCCN13
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Front Immunol
DMGV Is a Rheostat of T Cell Survival and a Potential Therapeutic for Inflammatory Diseases and Cancers. [Abstract]2022 Aug 5:13:918241. PMID: 35990633
용액&용해도
DMSO : 50 mg/mL (230.11 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (11.51 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (11.51 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (277 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Ghebremariam YT, et, al. A novel and potent inhibitor of dimethylarginine dimethylaminohydrolase: a modulator of cardiovascular nitric oxide. J Pharmacol Exp Ther. 2014 Jan; 348(1): 69-76. [Content Brief]
[2]. Chamoun-Emanuelli AM, et, al. Evaluation of PD 404,182 as an anti-HIV and anti-herpes simplex virus microbicide. Antimicrob Agents Chemother. 2014; 58(2): 687-97. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.6021 mL | 23.0107 mL | 46.0214 mL | 115.0536 mL |
| 5 mM | 0.9204 mL | 4.6021 mL | 9.2043 mL | 23.0107 mL | |
| 10 mM | 0.4602 mL | 2.3011 mL | 4.6021 mL | 11.5054 mL | |
| 15 mM | 0.3068 mL | 1.5340 mL | 3.0681 mL | 7.6702 mL | |
| 20 mM | 0.2301 mL | 1.1505 mL | 2.3011 mL | 5.7527 mL | |
| 25 mM | 0.1841 mL | 0.9204 mL | 1.8409 mL | 4.6021 mL | |
| 30 mM | 0.1534 mL | 0.7670 mL | 1.5340 mL | 3.8351 mL | |
| 40 mM | 0.1151 mL | 0.5753 mL | 1.1505 mL | 2.8763 mL | |
| 50 mM | 0.0920 mL | 0.4602 mL | 0.9204 mL | 2.3011 mL | |
| 60 mM | 0.0767 mL | 0.3835 mL | 0.7670 mL | 1.9176 mL | |
| 80 mM | 0.0575 mL | 0.2876 mL | 0.5753 mL | 1.4382 mL | |
| 100 mM | 0.0460 mL | 0.2301 mL | 0.4602 mL | 1.1505 mL |